Ibex Biosciences Revenue and Competitors

Unique to many Biotech startups, Ibex engages in a diverse and unique approach to Biotechnology, striving to discover, validate, and produce potential solutions to a multitude of medical challenges facing human and ecological health. Ibex has developed its programs "in-house," using ideas and techniques identified by its scientists and non-scientist managers. Ibex’s robust portfolio focuses on three primary areas: (1) Cancer and Non-Cancer Therapeutic antibodies / intrabody: Ibex is producing and developing antibodies targeting multiple cancers including breast, prostate, glioblastoma, lung, and neuroblastoma; (2) Cancer Gene Therapy: Ibex is developing a gene therapy that targets multiple cancer cells in-vitro including glioblastoma, melanoma, and cervical; and (3) Diagnostic Antibodies: Ibex is developing a skin cancer initial diagnostic, a CIN (Cervical Intraepithelial Neoplasia) diagnostic, and an early stage pancreatic cancer diagnostic.